Lipoic Acid Supplement for Cystine Stone

Completed · Phase 2 · Has a placebo group

Conditions studied: Cystinuria

In brief

This study evaluates how daily alpha lipoic acid supplementation affects cystine kidney stone recurrence. Half of the subjects will receive 1200 mg alpha lipoic acid orally daily for three years, while the other half will receive a placebo. The funding source for this clinical trial is FDA OOPD.

Key facts

Study ID

NCT02910531

Run by

Thomas Chi, MD

People needed

50

Starts

2017-06-19

Expected to finish

2024-12-18

Last updated by the study team

2026-04-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented cystinuria on prior 24-hour urine collection and/or stone analysis; history of previous cystine kidney stones.
• Being able and willing to provide consent.

You may not qualify if…

• Poorly controlled diabetes mellitus (hemoglobin A1C > 8.0% for more than 1 year).
• Current alpha-lipoic acid administration at the time of screening or within the last year prior to screening.
• Vulnerable populations including incarceration status.
• Unable to give informed consent.
• Non-English primary language.
• Pregnancy, lactation, or child-bearing age without birth control devices.
• Anticipation of pregnancy during the study period.
• Serious illness likely to cause death within the next 5 years.

Where it is running

• University of California, San Francisco — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.